HEADER IMMUNE SYSTEM 12-DEC-11 2LMS TITLE A SINGLE GALNAC RESIDUE ON THREONINE-106 MODIFIES THE DYNAMICS AND THE TITLE 2 STRUCTURE OF INTERFERON ALPHA-2A AROUND THE GLYCOSYLATION SITE COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTERFERON ALPHA-2; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: IFN-ALPHA-2, INTERFERON ALPHA-A, LEIF A; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: IFNA2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 9 EXPRESSION_SYSTEM_VARIANT: DE3; SOURCE 10 EXPRESSION_SYSTEM_VECTOR: PET-15B KEYWDS CYTOKINE, GLYCOPROTEIN, O-GLYCOSYLATION, SIGNALING PROTEIN, TYPE I KEYWDS 2 INTERFERONS, IMMUNE SYSTEM EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR H.GHASRIANI,P.J.F.BELCOURT,S.SAUVE,D.J.HODGSON,G.GINGRAS,D.BROCHU, AUTHOR 2 M.GILBERT,Y.AUBIN REVDAT 4 14-JUN-23 2LMS 1 HETSYN REVDAT 3 29-JUL-20 2LMS 1 COMPND REMARK SEQADV HETNAM REVDAT 3 2 1 LINK SITE ATOM REVDAT 2 01-MAY-13 2LMS 1 JRNL REVDAT 1 05-DEC-12 2LMS 0 JRNL AUTH H.GHASRIANI,P.J.BELCOURT,S.SAUVE,D.J.HODGSON,D.BROCHU, JRNL AUTH 2 M.GILBERT,Y.AUBIN JRNL TITL A SINGLE N-ACETYLGALACTOSAMINE RESIDUE AT THREONINE 106 JRNL TITL 2 MODIFIES THE DYNAMICS AND STRUCTURE OF INTERFERON ALPHA2A JRNL TITL 3 AROUND THE GLYCOSYLATION SITE. JRNL REF J.BIOL.CHEM. V. 288 247 2013 JRNL REFN ISSN 0021-9258 JRNL PMID 23184955 JRNL DOI 10.1074/JBC.M112.413252 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CYANA 2.1, CYANA REMARK 3 AUTHORS : GUNTERT, MUMENTHALER AND WUTHRICH (CYANA), REMARK 3 GUNTERT, MUMENTHALER AND WUTHRICH (CYANA) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2LMS COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 16-DEC-11. REMARK 100 THE DEPOSITION ID IS D_1000102574. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 298.15 REMARK 210 PH : 3.5 REMARK 210 IONIC STRENGTH : 25 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 0.85 MM [U-100% 13C; U-100% 15N] REMARK 210 INTERFERON ALPHA-2A (O- REMARK 210 GLYCOSYLATED), 90% H2O/10% D2O; REMARK 210 0.87 MM [U-100% 13C; U-100% 15N] REMARK 210 INTERFERON ALPHA-2A (O- REMARK 210 GLYCOSYLATED), 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D HNCO; 3D HNCA; 3D HNCACB; 3D REMARK 210 CBCA(CO)NH; 3D HBHA(CO)NH; 3D REMARK 210 HCCH-TOCSY; 3D 1H-15N NOESY; 3D REMARK 210 1H-13C NOESY ALIPHATIC; 3D 1H- REMARK 210 13C NOESY AROMATIC; 3D C(CO)NH; REMARK 210 2D (HB)CB(CGCD)HD; 2D (HB) REMARK 210 CB(CGCDCE)HE; 4D (C13)HSQC-NOESY- REMARK 210 (N15)HSQC; 4D (C13)HSQC-NOESY- REMARK 210 (C13)HSQC REMARK 210 SPECTROMETER FIELD STRENGTH : 700 MHZ; 600 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE; AVANCE III REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LEAST REMARK 210 RESTRAINT VIOLATIONS REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 465 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 MODELS 1-20 REMARK 465 RES C SSSEQI REMARK 465 MET A 0 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 PRO A 4 68.12 -69.83 REMARK 500 1 CYS A 29 88.97 -155.93 REMARK 500 1 ASP A 32 -31.51 -130.31 REMARK 500 1 ASP A 35 166.24 178.85 REMARK 500 1 PRO A 39 81.17 -69.79 REMARK 500 1 ASN A 45 73.05 -155.83 REMARK 500 1 PHE A 84 -74.62 -63.22 REMARK 500 1 SER A 163 103.60 -52.05 REMARK 500 2 LEU A 3 156.04 -46.97 REMARK 500 2 PRO A 4 65.92 -69.74 REMARK 500 2 CYS A 29 85.50 -157.43 REMARK 500 2 HIS A 34 81.24 62.07 REMARK 500 2 ASP A 35 -43.17 -132.08 REMARK 500 2 PRO A 39 81.30 -69.79 REMARK 500 2 PHE A 84 -72.61 -62.41 REMARK 500 3 LEU A 3 156.66 -48.74 REMARK 500 3 PRO A 4 64.05 -69.80 REMARK 500 3 CYS A 29 84.10 -159.18 REMARK 500 3 HIS A 34 100.24 60.39 REMARK 500 3 ASP A 35 -41.44 -151.88 REMARK 500 3 PRO A 39 83.72 -69.79 REMARK 500 3 ASN A 45 59.35 -149.82 REMARK 500 3 PHE A 84 -72.28 -62.93 REMARK 500 3 ASN A 156 63.63 -100.20 REMARK 500 3 LEU A 161 -74.98 -73.48 REMARK 500 4 LEU A 3 156.92 -47.92 REMARK 500 4 PRO A 4 68.57 -69.81 REMARK 500 4 CYS A 29 88.59 -155.29 REMARK 500 4 HIS A 34 89.22 51.52 REMARK 500 4 ASP A 35 -56.27 -139.26 REMARK 500 4 PRO A 39 81.85 -69.80 REMARK 500 4 PHE A 84 -72.05 -60.25 REMARK 500 4 SER A 136 168.41 -49.72 REMARK 500 5 LEU A 3 157.13 -47.93 REMARK 500 5 PRO A 4 76.06 -69.76 REMARK 500 5 CYS A 29 89.39 -153.67 REMARK 500 5 ASP A 35 -50.80 -166.91 REMARK 500 5 PRO A 39 75.29 -69.72 REMARK 500 5 ASN A 45 53.93 -151.46 REMARK 500 5 PHE A 84 -72.13 -62.75 REMARK 500 5 SER A 160 25.93 -151.47 REMARK 500 5 LEU A 161 -75.37 -92.36 REMARK 500 6 LEU A 3 158.73 -47.15 REMARK 500 6 PRO A 4 65.29 -69.81 REMARK 500 6 CYS A 29 88.56 -152.35 REMARK 500 6 HIS A 34 95.06 58.89 REMARK 500 6 ASP A 35 -50.65 -148.74 REMARK 500 6 PRO A 39 81.95 -69.80 REMARK 500 6 PHE A 84 -71.66 -59.47 REMARK 500 6 LYS A 164 39.16 -98.58 REMARK 500 REMARK 500 THIS ENTRY HAS 176 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 18135 RELATED DB: BMRB DBREF 2LMS A 1 165 UNP P01563 IFNA2_HUMAN 24 188 SEQADV 2LMS MET A 0 UNP P01563 INITIATING METHIONINE SEQRES 1 A 166 MET CYS ASP LEU PRO GLN THR HIS SER LEU GLY SER ARG SEQRES 2 A 166 ARG THR LEU MET LEU LEU ALA GLN MET ARG LYS ILE SER SEQRES 3 A 166 LEU PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE SEQRES 4 A 166 PRO GLN GLU GLU PHE GLY ASN GLN PHE GLN LYS ALA GLU SEQRES 5 A 166 THR ILE PRO VAL LEU HIS GLU MET ILE GLN GLN ILE PHE SEQRES 6 A 166 ASN LEU PHE SER THR LYS ASP SER SER ALA ALA TRP ASP SEQRES 7 A 166 GLU THR LEU LEU ASP LYS PHE TYR THR GLU LEU TYR GLN SEQRES 8 A 166 GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLY VAL SEQRES 9 A 166 GLY VAL THR GLU THR PRO LEU MET LYS GLU ASP SER ILE SEQRES 10 A 166 LEU ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR SEQRES 11 A 166 LEU LYS GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL SEQRES 12 A 166 VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER THR SEQRES 13 A 166 ASN LEU GLN GLU SER LEU ARG SER LYS GLU MODRES 2LMS THR A 106 THR GLYCOSYLATION SITE HET A2G A 500 28 HETNAM A2G 2-ACETAMIDO-2-DEOXY-ALPHA-D-GALACTOPYRANOSE HETSYN A2G N-ACETYL-ALPHA-D-GALACTOSAMINE; 2-ACETAMIDO-2-DEOXY- HETSYN 2 A2G ALPHA-D-GALACTOSE; 2-ACETAMIDO-2-DEOXY-D-GALACTOSE; 2- HETSYN 3 A2G ACETAMIDO-2-DEOXY-GALACTOSE; N-ACETYL-2-DEOXY-2-AMINO- HETSYN 4 A2G GALACTOSE FORMUL 2 A2G C8 H15 N O6 HELIX 1 1 LEU A 9 ARG A 22 1 14 HELIX 2 2 SER A 25 CYS A 29 5 5 HELIX 3 3 PRO A 39 GLY A 44 1 6 HELIX 4 4 GLU A 51 SER A 68 1 18 HELIX 5 5 THR A 69 TRP A 76 1 8 HELIX 6 6 ASP A 77 GLN A 101 1 25 HELIX 7 7 THR A 108 LYS A 133 1 26 HELIX 8 8 CYS A 138 ASN A 156 1 19 SSBOND 1 CYS A 1 CYS A 98 1555 1555 2.14 SSBOND 2 CYS A 29 CYS A 138 1555 1555 1.95 LINK OG1 THR A 106 C1 A2G A 500 1555 1555 1.54 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1